Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Marino Insider Profile
4 Followers
James Marino, Director at Traws Pharma, holds 21.33K shares in Traws Pharma (Ticker: TRAW), holds 12.70K shares in Celldex (Ticker: CLDX). Most recently, James Marino Bought ― shares of Traws Pharma on Sep 28, 2021 for an estimated value of 25.00K.
Profitable Transactions
2 out of 10 Profitable Transactions
Average Return
+14.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by James Marino
James Marino's Trading History
Traws Pharma
Sep 28, 2021
Director
Informative Buy
25.00K
$14.14K
Celldex
Jun 10, 2020
Director
Informative Buy
24.91K
$536.24K
List of latest transactions for each holding click on a transaction to see James Marino's performance on stock
You May Also Like
James Marino insider profile FAQ
What is the percentage of profitable transactions made by James Marino?
The percentage of profitable transactions made by James Marino is 20%.
What is the average return per transaction made by James Marino?
The average return per transaction made by James Marino is 14.40%.
What stocks does James Marino hold?
James Marino holds: TRAW, CLDX stocks.
What was James Marino’s latest transaction?
James Marino latest transaction was an Informative Buy of $25.00K.
What was James Marino's most profitable transaction?
James Marino’s most profitable transaction was an Informative Buy of CLDX stock on June 10, 2020. The return on the trade was 536.60%.
What is James Marino's role in Traws Pharma?
James Marino's role in Traws Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.